Related Experiment Video
Updated: Dec 16, 2025
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Perspectives in Manipulating EVs for Therapeutic Applications: Focus on Cancer Treatment
Katarzyna Nazimek1, Krzysztof Bryniarski1
1Department of Immunology, Faculty of Medicine, Jagiellonian University Medical College, 31-121 Krakow, Poland.
Abstract:
Extracellular vesicles (EVs) receive special attention from oncologists due to their assumed usefulness as prognostic markers, vaccines to induce anti-cancer immune response, and physiological delivery tools. The latter application, which supports the reduction of side effects of treatment, is still fraught with many challenges, including established methods for loading EVs with selected cargo and directing them towards target cells. EVs could be loaded with selected cargo either in vitro using several physicochemical techniques, or in vivo by modification of parental cell, which may have an advantage over in vitro procedures, since some of them significantly influence EVs' properties. Otherwise, our research findings suggest that EVs could be passively supplemented with micro RNAs (miRNAs) or miRNA antagonists to induce expected biological effect. Furthermore, our observations imply that antigen-specific antibody light chains could coat the surface of EVs to increase the specificity of cell targeting. Finally, the route of EVs' administration also determines their bioavailability and eventually induced therapeutic effect. Besides, EV membrane lipids may possibly possess immune adjuvant activity. The review summarizes the current knowledge on the possibilities to manipulate EVs to use them as a delivery tool, with the special emphasis on anti-cancer therapy.
Insights
Extracellular vesicles (EVs) show promise as anti-cancer tools. Researchers are exploring methods to load EVs with therapeutic cargo and target them for cancer treatment, potentially reducing side effects.
Area of Science:
- Oncology
- Biotechnology
- Nanomedicine
Background:
- Extracellular vesicles (EVs) are investigated for their potential in cancer therapy as prognostic markers, vaccine components, and drug delivery systems.
- Current challenges in utilizing EVs for cancer treatment include efficient cargo loading and targeted delivery to cancer cells.
- EVs offer a potential platform for reducing treatment side effects due to their physiological delivery capabilities.
Purpose of the Study:
- To review current knowledge on manipulating extracellular vesicles (EVs) for therapeutic applications in anti-cancer therapy.
- To highlight methods for loading EVs with therapeutic agents and enhancing their targeting specificity.
- To discuss the influence of administration routes and EV properties on therapeutic outcomes.
Main Methods:
- Review of existing literature on extracellular vesicle (EV) loading techniques (in vitro and in vivo).
- Analysis of strategies for modifying EVs, including passive supplementation with microRNAs (miRNAs) or miRNA antagonists.
- Evaluation of methods for enhancing EV targeting, such as coating with antibody light chains and considering EV membrane lipid properties.
Main Results:
- Both in vitro and in vivo methods exist for loading EVs, with in vivo modifications potentially preserving EV properties better.
- Passive supplementation with miRNAs or miRNA antagonists can induce biological effects, and antibody light chains can improve cell targeting.
- EV administration route significantly impacts bioavailability and therapeutic efficacy; EV lipids may have immune adjuvant properties.
Conclusions:
- Extracellular vesicles (EVs) can be engineered for targeted anti-cancer drug delivery.
- Further research into EV modification and administration is crucial for optimizing their therapeutic potential.
- EVs represent a promising, versatile platform for developing novel cancer therapies with potentially reduced side effects.
Related Concept Videos
01:36Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...